Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TKNO
TKNO logo

TKNO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Alpha Teknova Inc (TKNO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.890
1 Day change
7.84%
52 Week Range
7.480
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Alpha Teknova Inc (TKNO) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows slight revenue growth and improved gross margins, its declining net income and EPS, lack of significant trading trends, and absence of positive news or catalysts suggest limited upside potential. The technical indicators are neutral, and there are no strong proprietary trading signals or options data to support a buy decision.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 50.798, and moving averages are converging, indicating no clear trend. The stock is trading near support at 2.69 with resistance at 3.137, suggesting limited immediate upside.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
11

Positive Catalysts

  • Revenue increased by 7.76% YoY in Q4 2025, and gross margin improved by 49.07% YoY, indicating operational improvements.

Neutral/Negative Catalysts

  • Net income dropped by 16.80% YoY, and EPS declined by 18.18% YoY, reflecting worsening profitability. No significant news, trading trends, or congress trading activity to act as a catalyst.

Financial Performance

In Q4 2025, revenue increased to $9,984,000 (up 7.76% YoY), but net income dropped to -$4,758,000 (down 16.80% YoY). EPS declined to -0.09 (down 18.18% YoY), while gross margin improved to 29.62% (up 49.07% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast TKNO stock price to rise
4 Analyst Rating
Wall Street analysts forecast TKNO stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.680
sliders
Low
7
Averages
7
High
7
Current: 2.680
sliders
Low
7
Averages
7
High
7
Stephens
Stephens
maintain
$8
AI Analysis
2025-07-21
Reason
Stephens
Stephens
Price Target
$8
AI Analysis
2025-07-21
maintain
Reason
Stephens resumed coverage of Alpha Teknova with an Overweight rating and $8 price target. The company will benefit from growth in the biologics end market, the analyst tells investors in a research note. The firm believes Alpha continues to add to its clinical solutions customer base, which should drive revenue growth as demand ramps.

People Also Watch